CD47 and acute myeloid leukemia: Previous studies have shown a high incidence of grade 3 and 4 treatment-related adverse events, including anemia, neutropenia, and thrombocytopenia, in patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) with the CD47 antibody Hu5F9-G4 even at low doses [27].